A Phase 1/2 interventional study of Etentamig and Lenalidomide in Multiple Myeloma, sponsored by AbbVie. Recruiting at 36 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment
Substudy 7: ABBV-2001 Dose Escalation · Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 1 · Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 2 · Substudy 8: ABBV-2001 Dose Escalation · Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 1 · Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 2
Substudy 1: Comparator · Substudy 2: Comparator · Substudy 3: Etentamig Dose Expansion Dose Level 1 · Substudy 3: Etentamig Dose Expansion Dose Level 2 · Substudy 3: Comparator · Substudy 4: Etentamig Dose Expansion Dose Level 1 · Substudy 4: Etentamig Dose Expansion Dose Level 2
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing etentamig in Multiple Myeloma — 6 open to participants now, 10 under way, 3 of them phase 3. etentamig · Multiple Myeloma.
Among the 10 studies testing etentamig in Multiple Myeloma, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 1/2, and was the 6th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →6 of the 10 studies testing etentamig in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Israel, Japan and 1 more country
Ages 18+
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
AbbVie · Sites in United States, Australia, Canada and 4 more countries
Ages 18+
AbbVie · Sites in United States, Canada, Denmark and 4 more countries
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 3
First in 2019; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 602 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 235 across the 10 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 2 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
40 studies in Multiple Myeloma by AbbVie: 7 open now, 17 under way, 5 of them phase 3. Of 21 finished, 8 (38%) have results posted.
Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 2nd largest by planned enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 in phase 1/2, reaches primary completion later than 14 of the 16 other live ones, and was the 35th registered.
AbbVie’s Multiple Myeloma studies by the year they started, since 2005.
1 of the studies testing etentamig in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06223516AbbVieStudy of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing etentamig in Multiple Myeloma, from their registry updates:
Among AbbVie’s 40 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig and ABBV-2001 in adult participants with MM.
Etentamig and ABBV-2001 are investigational drugs being developed for the treatment of MM. This study is broken into 8 substudies and each substudy consists of a dose escalation phase and dose expansion phase. Participants in substudies 1-4 will receive escalating doses of etentamig alone or with daratumumab and lenalidomide (DR), carfilzomib and dexamethasone (Kd) or lenalidomide (R), followed by etentamig at the dose levels established during the escalation phases alone or with DR, Kd and R. Participants in substudies 5-8 will receive up to two doses of ABBV-2001 or at the dose level(s) established during the escalation phases of ABBV-2001 with iberdomide, mezigdomide, pomalidomide or lenalidomide. Around 602 adult participants with MM will be enrolled at approximately 55 sites worldwide
In substudies 1-3, participants will receive escalating doses of etentamig as Intravenous (IV) infusions, alone or with DR, R or Kd, followed by SC injections of etentamig at the dose levels established during the escalation phases alone or with DR or K. In substudy 4, participants will receive escalating doses of etentamig as Intravenous (IV) infusions followed by SC injections of etentamig at the dose levels established during the escalation phase with Lenalidomide. In substudies 5-8, participants will receive up to two doses of ABBV-2001 as subcutaneous (SC) injections, with oral iberdomide, mezigdomide, pomalidomide or lenalidomide followed by SC injections of ABBV-2001 at the dose level(s) established during the escalation phases with oral iberdomide, mezigdomide, pomalidomide or lenalidomide. The study duration is approximately 130 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive escalating etentamig in combination with daratumumab, and lenalidomide (DR), as part of the approximately 130 month study duration.
Drug: Etentamig · Drug: Lenalidomide · Drug: Daratumumab
Participants will receive a recommended dose of etentamig in combination with DR, as part of the approximately 130 month study duration.
Drug: Etentamig · Drug: Lenalidomide · Drug: Daratumumab
Participants will receive escalating etentamig, as part of the approximately 130 month study duration.
Drug: Etentamig
Participants will receive a recommended dose of etentamig, as part of the approximately 130 month study duration.
Drug: Etentamig
Participants will receive escalating etentamig in combination with carfilzomib, and dexamethasone (Kd), as part of the approximately 130 month study duration.
Drug: Etentamig · Drug: Dexamethasone · Drug: Carfilzomib
Participants will receive a recommended dose of etentamig in combination with carfilzomib (k), as part of the approximately 130 month study duration.
Drug: Etentamig · Drug: Dexamethasone · Drug: Carfilzomib
Participants will receive escalating etentamig in combination with R, as part of the approximately 130 month study duration.
Drug: Etentamig · Drug: Lenalidomide
Participants will receive a recommended dose of etentamig in combination with R, as part of the approximately 130 month study duration.
Drug: Etentamig · Drug: Lenalidomide
Participants will receive up to two doses of ABBV-2001 in combination with iberdomide, as part of the approximately 130 month study duration.
Drug: Iberdomide · Drug: ABBV-2001
Participants will receive ABBV-2001 in combination with iberdomide at the combo dose level 1, as part of the approximately 130 month study duration.
Drug: Iberdomide · Drug: ABBV-2001
Participants will receive ABBV-2001 in combination with iberdomide, at the combo dose level 2, as part of the approximately 130-month study duration.
Drug: Iberdomide · Drug: ABBV-2001
Participants will receive up to two doses of ABBV-2001 in combination with mezigdomide, as part of the approximately 130 month study duration.
Drug: Mezigdomide · Drug: ABBV-2001
Participants will receive ABBV-2001 in combination with mezigdomide, at the combo dose level 1, as part of the approximately 130-month study duration.
Drug: Mezigdomide · Drug: ABBV-2001
Participants will receive ABBV-2001 in combination with mezigdomide, at the combo dose level 2, as part of the approximately 130-month study duration.
Drug: Mezigdomide · Drug: ABBV-2001
Participants will receive up to two doses of ABBV-2001 in combination with pomalidomide, as part of the approximately 130 month study duration.
Drug: ABBV-2001 · Drug: Pomalidomide
Participants will receive ABBV-2001 in combination with pomalidomide, at the combo dose level 1, as part of the approximately 130-month study duration.
Drug: ABBV-2001 · Drug: Pomalidomide
Participants will receive ABBV-2001 in combination with pomalidomide, at the combo dose level 2, as part of the approximately 130-month study duration.
Drug: ABBV-2001 · Drug: Pomalidomide
Participants will receive up to two doses of ABBV-2001 in combination with lenalidomide, as part of the approximately 130 month study duration.
Drug: Lenalidomide · Drug: ABBV-2001
Participants will receive ABBV-2001 in combination with lenalidomide, at the combo dose level 1, as part of the approximately 130-month study duration.
Drug: Lenalidomide · Drug: ABBV-2001
Participants will receive ABBV-2001 in combination with lenalidomide, at the combo dose level 2, as part of the approximately 130-month study duration.
Drug: Lenalidomide · Drug: ABBV-2001
Intravenous (IV) Infusion
Oral
IV Injection
Subcutaneous (SC) Injection
Oral
Intravenous (IV) Infusion
Oral
Oral
Subcutaneous (SC) Injection
Subcutaneous (SC) Injection
Oral
Number of Participants with Adverse Events (AE)s
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Approximately 130 Months
Substudy 1: Dose-Limiting Toxicity (DLT) of Etentamig + Daratumumab and Lenalidomide (DR) in Participants with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM)
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
Time frame: Up to Approximately 8 weeks
Substudy 2: DLT of Etentamig Monotherapy as Maintenance in Participants with Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM)
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
Time frame: Up to Approximately 8 Weeks
Substudy 3: DLT of Etentamig +Carfilzomib and Dexamethasone (Kd) Combination in Participants with Relapsed or Refractory Multiple Myeloma (RR MM)
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
Time frame: Up to Approximately 8 Weeks
Substudy 4: DLT of Etentamig plus Lenalidomide when Given as Maintenance in Participants with TE NDMM
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
Time frame: Up to Approximately 8 Weeks
Substudy 5: DLT of ABBV-2001 in Combination with Iberdomide in Participants with RR MM
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
Time frame: Up to Approximately 8 Weeks
Substudy 6: DLT of ABBV-2001 in Combination with Mezigdomide in Participants with RR MM
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
Time frame: Up to Approximately 8 Weeks
Substudy 7: DLT of ABBV-2001 in Combination with Pomalidomide in Participants with RR MM
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
Time frame: Up to Approximately 8 Weeks
Substudy 8: DLT of ABBV-2001 in Combination with Lenalidomide in Participants with RR MM
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
Time frame: Up to Approximately 8 Weeks
Substudy 1, 2, 3, 4, 5, 6, 7, 8: Complete Response Rate
Complete response rate is defined as complete response (CR), stringent complete response (sCR) as assessed by the international myeloma working group (IMWG) 2016 criteria for MM.
Time frame: Up to Approximately 1 Year
Substudy 1, 2, 3, 4, 5, 6, 7, 8: Overall Response Rate (ORR)
The ORR is defined as the percentage of participants who achieve a best overall response of confirmed PR or better determined by IMWG criteria, prior to the initiation of subsequent myeloma therapy.
Time frame: Up to Approximately 1 Year
Substudy 1, 2, 3, 4, 5, 6, 7, 8: Progression Free Survival (PFS)
PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (determined by the IMWG) or death.
Time frame: Up to Approximately 130 Months
Substudy 1, 2, 3, 4, 5, 6, 7, 8: Duration of Response (DOR)
DOR is defined as the time from the date of first response to the earliest occurrence of progressive disease, or death, whatever occurs first.
Time frame: Up to Approximately 130 Months
Substudy 1, 2, 3, 4, 5, 6, 7, 8: Time-to-Progression (TTP)
TTP will be defined as the number of days from the date of first dose to the date of earliest disease progression.
Time frame: Up to Approximately 130 Months
Substudy 1, 2, 3, 4, 5, 6, 7, 8: Minimal Residual Disease (MRD) negativity
The MRD negativity rate is defined as the proportion of participants who achieve MRD negative status.
Time frame: Up to Approximately 52 Weeks
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2035, 126 months after the start.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 126 months is above that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2035 → Mar 2036, on Oct 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Substudy 7: ABBV-2001 Dose Escalation · Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 1 · Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 2 · Substudy 8: ABBV-2001 Dose Escalation · Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 1 · Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 2
Substudy 1: Comparator · Substudy 2: Comparator · Substudy 3: Etentamig Dose Expansion Dose Level 1 · Substudy 3: Etentamig Dose Expansion Dose Level 2 · Substudy 3: Comparator · Substudy 4: Etentamig Dose Expansion Dose Level 1 · Substudy 4: Etentamig Dose Expansion Dose Level 2
Substudy 7: ABBV-2001 Dose Escalation · Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 1 · Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 2 · Substudy 8: ABBV-2001 Dose Escalation · Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 1 · Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 2
Substudy 1: Comparator · Substudy 2: Comparator · Substudy 3: Etentamig Dose Expansion Dose Level 1 · Substudy 3: Etentamig Dose Expansion Dose Level 2 · Substudy 3: Comparator · Substudy 4: Etentamig Dose Expansion Dose Level 1 · Substudy 4: Etentamig Dose Expansion Dose Level 2
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Etentamig · Lenalidomide